http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2006280175-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N57-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
filingDate | 2006-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae6989eaed8987a111b5b27b3984322c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70e247f97f592195e546568e51e94218 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c5bad3a83ecc84d69d10c52f72f0c93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eafb6b743e43487368e4de1831453b56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_905e51dcdbe09990bf9c9550c978b6e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d40193c525e992faaac582b587aaf0bb |
publicationDate | 2011-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2006280175-B2 |
titleOfInvention | Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection |
abstract | The present invention provides ribonucleoside 2’,3’-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2’,3’-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the ribonucleoside 2’,3’-cyclic acetals of the present invention. |
priorityDate | 2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1214.